Effect of Nucleoside and Nucleotide Analogues on Renal Function in Patients With Chronic Hepatitis B VirusMonoinfection

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 6, 2015, Pages 1181-1188.e1

  Mallet, Vincent ^a,b,c,d   Schwarzinger, Michaël ^e   Vallet Pichard, Anaïs ^d   Fontaine, Hélène ^d   Corouge, Marion ^d   Sogni, Philippe ^a,b,c,d   Pol, Stanislas ^a,b,c,d  

^a INSTITUT COCHIN   (France)

^b CNRS   (France)

^c INSERM   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e Translational Health Economics Network   (France)

Author keywords

Antiviral; BeSafe Study; Chronic Kidney Disease; Drug; Mixed Linear Model

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; TENOFOVIR DISOPROXIL; VIRUS DNA; ANTIVIRUS AGENT; GUANINE; TENOFOVIR;

ADULT; AGE; AGED; ARTICLE; CHRONIC HEPATITIS B; COHORT ANALYSIS; COMORBIDITY; DRUG EFFECT; ENDEMIC DISEASE; FACTORIAL ANALYSIS; FEMALE; GEOGRAPHIC ORIGIN; GLOMERULUS FILTRATION RATE; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION CONTROL; KIDNEY DYSFUNCTION; LIVER FIBROSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NONHUMAN; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; REFERENCE VALUE; RETROSPECTIVE STUDY; RISK FACTOR; SEX; ANALOGS AND DERIVATIVES; DRUG EFFECTS; FRANCE; HEPATITIS B, CHRONIC; KIDNEY; MIDDLE AGED;

ADULT; ANTIVIRAL AGENTS; FEMALE; FRANCE; GLOMERULAR FILTRATION RATE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; KIDNEY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; TENOFOVIR;

EID: 84930373722     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.11.021     Document Type: Article

References (31)

1. Combes B., Shorey J., Barrera A., et al. Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane. Lancet 1971, 2:234-237.
2. Knecht G.L., Chisari F.V. Reversibility of hepatitis B virus-induced glomerulonephritis and chronic active hepatitis after spontaneous clearance of serum hepatitis B surface antigen. Gastroenterology 1978, 75:1152-1156.
3. Conjeevaram H.S., Hoofnagle J.H., Austin H.A., et al. Long-term outcome of hepatitis B virus-related glomerulonephritis aftertherapy with interferon alfa. Gastroenterology 1995, 109:540-546.
4. EASL Clinical Practice Guidelines. Management of chronic hepatitis B virus infection. JHepatol 2012, 57:167-185.
5. Fontana R.J. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009, 49:S185-S195.
6. Izzedine H., Launay-Vacher V., Isnard-Bagnis C., et al. Antiviral drug-induced kidney and electrolytes disorders. Minerva Urol Nefrol 2003, 55:157-172.
7. Gane E.J., Deray G., Liaw Y.F., et al. Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology 2014, 146:138-146 e5.
8. Mauss S., Berger F., Filmann N., et al. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. JHepatol 2011, 55:1235-1240.
9. Gish R.G., Clark M.D., Kane S.D., et al. Similar risk of renal eventsamong patients treated with tenofovir or entecavir for chronic hepatitis B. Clin Gastroenterol Hepatol 2012, 10:941-946. quiz e68.
10. Lampertico P., Vigano M., Yurdaydin C., et al. Effectiveness and safety of tenofovir disoproxil fumarate in field practice: a multicenter European cohort study of 737 patients with chronic hepatitis B. Hepatology 2010, 52. 503A-A.
11. van Bommel F., de Man R., Ferenci P., et al. Evaluation of safety and tolerability of tenofovir DF (TDF) long term monotherapy in nucleos(t)ide analogue experienced patients with HBV monoinfection. JHepatol 2009, 50. S338-S.
12. Charlson M.E., Pompei P., Ales K.L., et al. Anew method of classifying prognostic comorbidity in longitudinal studies: development and validation. JChronic Dis 1987, 40:373-383.
13. Stevens P.E., Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 2013, 158:825-830.
14. Massy Z.A., Khoa T.N., Lacour B., et al. Dyslipidaemia and the progression of renal disease in chronic renal failure patients. Nephrol Dial Transplant 1999, 14:2392-2406.
15. Qaseem A., Hopkins J.R.H., Sweet D.E., et al. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2013, 159:835-847.
16. Chang T.T., Lai C.L., Kew Yoon S., et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010, 51:422-430.
17. Heathcote E.J., Marcellin P., Buti M., et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011, 140:132-143.
18. Lampertico P., Soffredini R., Vigano M., et al. Entecavir treatment for NUC naive, field practice patients with chronic hepatitis B: excellent viral suppression and safety profile over 5 years of treatment. Hepatology 2012, 56:370A-371A.
19. Lampertico P., Soffredini R., Vigano M., et al. Tenofovir monotherapy suppressed viral suppression in most field practice, treatment-naive patients with chronic hepatitis B followed for 3 years in a multicenter European study. Hepatology 2012, 56. 389A-A.
20. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. NEngl J Med 2003, 348:800-807.
21. Marcellin P., Chang T.T., Lim S.G., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. NEngl J Med 2003, 348:808-816.
22. Amet S., Bronowicki J.P., Thabut D., et al. Prevalence of renal abnormalities in chronic HBV infection: the HARPE study. Liver Int 2015, 35:148-155.
23. Deterding K., Lampe N., Reijnders J., et al. Prevalence and severity of kidney dysfunction in patients with chronic hepatitis B in Europe: data from the European Virgil Cohort. JHepatol 2011, 54. S147-S.
24. Gish R.G., Mangahas M.F., Baqai S.F., et al. Risk of renal toxicity with tenofovir DF (TDF) for chronic hepatitis B (CHB). Hepatology 2010, 52. 529A-A.
25. Lai K.N., Li P.K., Lui S.F., et al. Membranous nephropathy related to hepatitis B virus in adults. NEngl J Med 1991, 324:1457-1463.
26. Fontaine H., Vallet-Pichard A., Chaix M.L., et al. Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation 2005, 80:1086-1092.
27. Okuse C., Yotsuyanagi H., Yamada N., et al. Successful treatment of hepatitis B virus-associated membranous nephropathy with lamivudine. Clin Nephrol 2006, 65:53-56.
28. Marcellin P., Gane E., Buti M., et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013, 381:468-475.
29. Gracey D.M., Snelling P., McKenzie P., et al. Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection. Antivir Ther 2013, 18:945-948.
30. Vigano M., Lampertico P., Soffredini R., et al. The course of bone mineral density in patients with chronic hepatitis B long-term treated with nucleos(t)ide analogs: a longitudinal cohort study. Hepatology 2011, 54. 1016A-A.
31. Levey A.S., Stevens L.A., Schmid C.H., et al. Anew equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150:604-612.